A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.jCr9XYTz.js ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

A new study shows that GLP-1 drugs offer health benefits such as reducing risks for heart disease but also carry potential risks like gastrointestinal issues.